Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 1 Mean change in total lesion count.
Figuras y tablas -
Analysis 1.1

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 1 Mean change in total lesion count.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 2 Mean change in inflammatory lesion count.
Figuras y tablas -
Analysis 1.2

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 2 Mean change in inflammatory lesion count.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 3 Mean change in non‐inflammatory lesion count.
Figuras y tablas -
Analysis 1.3

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 3 Mean change in non‐inflammatory lesion count.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 4 Clinician assessment of women with clear or almost clear lesions at cycle 6.
Figuras y tablas -
Analysis 1.4

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 4 Clinician assessment of women with clear or almost clear lesions at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 5 Participant self‐assessment of acne lesion improvement.
Figuras y tablas -
Analysis 1.5

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 5 Participant self‐assessment of acne lesion improvement.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 6 Discontinuation due to non‐acne adverse event.
Figuras y tablas -
Analysis 1.6

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 6 Discontinuation due to non‐acne adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 7 Discontinuation due to lack of acne improvement.
Figuras y tablas -
Analysis 1.7

Comparison 1 LNG 100 µg / EE 20 µg versus placebo, Outcome 7 Discontinuation due to lack of acne improvement.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 NA 1 mg / EE 20‐30‐35 µg versus placebo, Outcome 1 Clinician assessment of no, minimal or mild acne at cycle 6.
Figuras y tablas -
Analysis 2.1

Comparison 2 NA 1 mg / EE 20‐30‐35 µg versus placebo, Outcome 1 Clinician assessment of no, minimal or mild acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 NA 1 mg / EE 20‐30‐35 µg versus placebo, Outcome 2 Discontinuation due to any adverse event.
Figuras y tablas -
Analysis 2.2

Comparison 2 NA 1 mg / EE 20‐30‐35 µg versus placebo, Outcome 2 Discontinuation due to any adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 1 Mean change in total lesion count at cycle 6.
Figuras y tablas -
Analysis 3.1

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 1 Mean change in total lesion count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 2 Mean change in inflammatory lesion count at cycle 6.
Figuras y tablas -
Analysis 3.2

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 2 Mean change in inflammatory lesion count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 3 Mean change in comedone count at cycle 6.
Figuras y tablas -
Analysis 3.3

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 3 Mean change in comedone count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 4 Clinician global assessment of improved acne at cycle 6.
Figuras y tablas -
Analysis 3.4

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 4 Clinician global assessment of improved acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 5 Participant self‐assessment of improved acne at cycle 6.
Figuras y tablas -
Analysis 3.5

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 5 Participant self‐assessment of improved acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 6 Discontinuation due to non‐acne adverse event.
Figuras y tablas -
Analysis 3.6

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 6 Discontinuation due to non‐acne adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 7 Discontinuation due to worsening of acne.
Figuras y tablas -
Analysis 3.7

Comparison 3 NGM 180‐215‐250 µg / EE 35 µg versus placebo, Outcome 7 Discontinuation due to worsening of acne.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 1 Mean percentage change in inflammatory lesion count after cycle 6.
Figuras y tablas -
Analysis 4.1

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 1 Mean percentage change in inflammatory lesion count after cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 2 Mean percentage change in total lesion count after cycle 6.
Figuras y tablas -
Analysis 4.2

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 2 Mean percentage change in total lesion count after cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 3 Improvement of facial acne (clinical assessment).
Figuras y tablas -
Analysis 4.3

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 3 Improvement of facial acne (clinical assessment).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 4 Discontinuation due to adverse event.
Figuras y tablas -
Analysis 4.4

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 4 Discontinuation due to adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 5 Discontinuation due to reason other than adverse event.
Figuras y tablas -
Analysis 4.5

Comparison 4 Dienogest 2 mg / EE 30 µg versus placebo, Outcome 5 Discontinuation due to reason other than adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 1 Mean percent change in lesion counts at cycle 6.
Figuras y tablas -
Analysis 5.1

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 1 Mean percent change in lesion counts at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 2 Clear or almost clear (investigator assessment) at cycle 6.
Figuras y tablas -
Analysis 5.2

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 2 Clear or almost clear (investigator assessment) at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 3 Participants classified as 'improved' at cycle 6.
Figuras y tablas -
Analysis 5.3

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 3 Participants classified as 'improved' at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 4 Discontinuation.
Figuras y tablas -
Analysis 5.4

Comparison 5 DRSP 3 mg / EE 20 µg versus placebo, Outcome 4 Discontinuation.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 CMA 2 mg / EE 30 µg versus placebo, Outcome 1 Responders (>= 50% decrease in facial papules and pustules) at cycle 6.
Figuras y tablas -
Analysis 6.1

Comparison 6 CMA 2 mg / EE 30 µg versus placebo, Outcome 1 Responders (>= 50% decrease in facial papules and pustules) at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 CMA 2 mg / EE 30 µg versus placebo, Outcome 2 Discontinuation due to adverse event.
Figuras y tablas -
Analysis 6.2

Comparison 6 CMA 2 mg / EE 30 µg versus placebo, Outcome 2 Discontinuation due to adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 DRSP 3 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean percentage change in total acne count at cycle 9.
Figuras y tablas -
Analysis 7.1

Comparison 7 DRSP 3 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean percentage change in total acne count at cycle 9.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 DRSP 3 mg / EE 30 µg versus LNG 150 µg / EE 30 µg, Outcome 1 Discontinuation due to acne deterioration.
Figuras y tablas -
Analysis 8.1

Comparison 8 DRSP 3 mg / EE 30 µg versus LNG 150 µg / EE 30 µg, Outcome 1 Discontinuation due to acne deterioration.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 1 Mean percentage change in inflammatory lesion count after cycle 6.
Figuras y tablas -
Analysis 9.1

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 1 Mean percentage change in inflammatory lesion count after cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 2 Mean percentage change in total lesion count after cycle 6.
Figuras y tablas -
Analysis 9.2

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 2 Mean percentage change in total lesion count after cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 3 Discontinuation due to adverse event.
Figuras y tablas -
Analysis 9.3

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 3 Discontinuation due to adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 4 Discontinuation due to reason other than adverse event.
Figuras y tablas -
Analysis 9.4

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 4 Discontinuation due to reason other than adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 5 Improvement of facial acne (clinical assessment).
Figuras y tablas -
Analysis 9.5

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 5 Improvement of facial acne (clinical assessment).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 6 Improvement of facial acne (subject assessment).
Figuras y tablas -
Analysis 9.6

Comparison 9 DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg, Outcome 6 Improvement of facial acne (subject assessment).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 1 Clinician assessment of improved acne after cycle 13 (all participants).
Figuras y tablas -
Analysis 10.1

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 1 Clinician assessment of improved acne after cycle 13 (all participants).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 2 Clinician assessment of worsening acne after cycle 13 (all participants).
Figuras y tablas -
Analysis 10.2

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 2 Clinician assessment of worsening acne after cycle 13 (all participants).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 3 Clinician assessment of improved acne after cycle 13 (participants with acne at baseline).
Figuras y tablas -
Analysis 10.3

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 3 Clinician assessment of improved acne after cycle 13 (participants with acne at baseline).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 4 Clinician assessment of worsening acne after cycle 13 (participants with acne at baseline).
Figuras y tablas -
Analysis 10.4

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 4 Clinician assessment of worsening acne after cycle 13 (participants with acne at baseline).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 5 Clinician assessment of new acne after cycle 13 (participants without acne at baseline).
Figuras y tablas -
Analysis 10.5

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 5 Clinician assessment of new acne after cycle 13 (participants without acne at baseline).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 6 Discontinuation due to adverse events.
Figuras y tablas -
Analysis 10.6

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 6 Discontinuation due to adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 7 Discontinuation due to acne.
Figuras y tablas -
Analysis 10.7

Comparison 10 NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg, Outcome 7 Discontinuation due to acne.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Photographic evaluation of mean change in acne at cycle 4.
Figuras y tablas -
Analysis 11.1

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Photographic evaluation of mean change in acne at cycle 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Women with pustules or nodules at cycle 4.
Figuras y tablas -
Analysis 11.2

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Women with pustules or nodules at cycle 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 3 Mean change in comedone count at cycle 4.
Figuras y tablas -
Analysis 11.3

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 3 Mean change in comedone count at cycle 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 4 Mean change in papule count at cycle 4.
Figuras y tablas -
Analysis 11.4

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 4 Mean change in papule count at cycle 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 5 Mean change in pustule count at cycle 4.
Figuras y tablas -
Analysis 11.5

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 5 Mean change in pustule count at cycle 4.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 6 Women with moderate acne at cycle 6.
Figuras y tablas -
Analysis 11.6

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 6 Women with moderate acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 7 Women with severe acne at cycle 6.
Figuras y tablas -
Analysis 11.7

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 7 Women with severe acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 8 Mean comedone count at cycle 6.
Figuras y tablas -
Analysis 11.8

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 8 Mean comedone count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 9 Mean papule count at cycle 6.
Figuras y tablas -
Analysis 11.9

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 9 Mean papule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 10 Mean postule count at cycle 6.
Figuras y tablas -
Analysis 11.10

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 10 Mean postule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 11 Mean nodule count at cycle 6.
Figuras y tablas -
Analysis 11.11

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 11 Mean nodule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 12 Discontinuation due to non‐acne adverse event.
Figuras y tablas -
Analysis 11.12

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 12 Discontinuation due to non‐acne adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 13 Discontinuation due to worsening of acne.
Figuras y tablas -
Analysis 11.13

Comparison 11 DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg, Outcome 13 Discontinuation due to worsening of acne.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Women with moderate or severe acne at cycle 6.
Figuras y tablas -
Analysis 12.1

Comparison 12 DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Women with moderate or severe acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 2 Women with self‐assessed acne improvement at cycle 6.
Figuras y tablas -
Analysis 12.2

Comparison 12 DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 2 Women with self‐assessed acne improvement at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 3 Discontinuation due to side effects.
Figuras y tablas -
Analysis 12.3

Comparison 12 DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 3 Discontinuation due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 1 Women without acne at cycle 6.
Figuras y tablas -
Analysis 13.1

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 1 Women without acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 2 Women with mild acne at cycle 6.
Figuras y tablas -
Analysis 13.2

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 2 Women with mild acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 3 Women with moderate or severe acne at cycle 6.
Figuras y tablas -
Analysis 13.3

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 3 Women with moderate or severe acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 4 Women with mild or no acne at cycle 9.
Figuras y tablas -
Analysis 13.4

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 4 Women with mild or no acne at cycle 9.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 5 Women with improved acne score at cycle 9.
Figuras y tablas -
Analysis 13.5

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 5 Women with improved acne score at cycle 9.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 6 Discontinuation due to side effects.
Figuras y tablas -
Analysis 13.6

Comparison 13 DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg, Outcome 6 Discontinuation due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 1 Improvement in comedones at week 25.
Figuras y tablas -
Analysis 14.1

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 1 Improvement in comedones at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 2 Worsening in comedones at week 25.
Figuras y tablas -
Analysis 14.2

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 2 Worsening in comedones at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 3 Improvement in papules at week 25.
Figuras y tablas -
Analysis 14.3

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 3 Improvement in papules at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 4 Worsening in papules at week 25.
Figuras y tablas -
Analysis 14.4

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 4 Worsening in papules at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 5 Improvement in pustules at week 25.
Figuras y tablas -
Analysis 14.5

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 5 Improvement in pustules at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 6 Worsening in pustules at week 25.
Figuras y tablas -
Analysis 14.6

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 6 Worsening in pustules at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 7 Improvement in nodules at week 25.
Figuras y tablas -
Analysis 14.7

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 7 Improvement in nodules at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 8 Worsening in nodules at week 25.
Figuras y tablas -
Analysis 14.8

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 8 Worsening in nodules at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 9 Scores for Psychological General Well‐Being Index at week 13.
Figuras y tablas -
Analysis 14.9

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 9 Scores for Psychological General Well‐Being Index at week 13.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 10 Scores for Psychological General Well‐Being Index at week 25.
Figuras y tablas -
Analysis 14.10

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 10 Scores for Psychological General Well‐Being Index at week 25.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 11 Adverse events related to treatment.
Figuras y tablas -
Analysis 14.11

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 11 Adverse events related to treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 12 Adverse events not related to treatment.
Figuras y tablas -
Analysis 14.12

Comparison 14 DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg, Outcome 12 Adverse events not related to treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 1 Mean acne severity score at cycle 6.
Figuras y tablas -
Analysis 15.1

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 1 Mean acne severity score at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 2 Mean total lesion count at cycle 9.
Figuras y tablas -
Analysis 15.2

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 2 Mean total lesion count at cycle 9.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 3 Discontinuation due to side effects.
Figuras y tablas -
Analysis 15.3

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 3 Discontinuation due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 4 Discontinuation due to worsening acne.
Figuras y tablas -
Analysis 15.4

Comparison 15 LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg, Outcome 4 Discontinuation due to worsening acne.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 1 Women with >= 50% reduction in pustules and papules at cycle 12.
Figuras y tablas -
Analysis 16.1

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 1 Women with >= 50% reduction in pustules and papules at cycle 12.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 2 Women with Plewig score of 0 at cycle 12.
Figuras y tablas -
Analysis 16.2

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 2 Women with Plewig score of 0 at cycle 12.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 3 Women with increased pustules or papules lesion count at cycle 12.
Figuras y tablas -
Analysis 16.3

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 3 Women with increased pustules or papules lesion count at cycle 12.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 4 Women with comedones improvement at cycle 12.
Figuras y tablas -
Analysis 16.4

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 4 Women with comedones improvement at cycle 12.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 5 Women with self‐assessed acne improvement at cycle 12.
Figuras y tablas -
Analysis 16.5

Comparison 16 LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg, Outcome 5 Women with self‐assessed acne improvement at cycle 12.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean change in total acne lesions at cycle 6.
Figuras y tablas -
Analysis 17.1

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean change in total acne lesions at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Mean pustule count at cycle 6.
Figuras y tablas -
Analysis 17.2

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Mean pustule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 3 Mean papule count at cycle 6.
Figuras y tablas -
Analysis 17.3

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 3 Mean papule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 4 Mean cyst and nodule count at cycle 6.
Figuras y tablas -
Analysis 17.4

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 4 Mean cyst and nodule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 5 Women with dermatologist global "good" acne assessment at cycle 6.
Figuras y tablas -
Analysis 17.5

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 5 Women with dermatologist global "good" acne assessment at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 6 Women with "good" acne self‐assessment at cycle 6.
Figuras y tablas -
Analysis 17.6

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 6 Women with "good" acne self‐assessment at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 7 Discontinuation due to side effects.
Figuras y tablas -
Analysis 17.7

Comparison 17 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 7 Discontinuation due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Mean change in total acne lesions at cycle 6.
Figuras y tablas -
Analysis 18.1

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Mean change in total acne lesions at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 2 Mean pustule count at cycle 6.
Figuras y tablas -
Analysis 18.2

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 2 Mean pustule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 3 Mean papule count at cycle 6.
Figuras y tablas -
Analysis 18.3

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 3 Mean papule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 4 Mean cyst and nodule count at cycle 6.
Figuras y tablas -
Analysis 18.4

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 4 Mean cyst and nodule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 5 Women with dermatologist global "good" acne assessment at cycle 6.
Figuras y tablas -
Analysis 18.5

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 5 Women with dermatologist global "good" acne assessment at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 6 Women with "good" acne self‐assessment at cycle 6.
Figuras y tablas -
Analysis 18.6

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 6 Women with "good" acne self‐assessment at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 7 Discontinuation due to side effects.
Figuras y tablas -
Analysis 18.7

Comparison 18 LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg, Outcome 7 Discontinuation due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 LNG 250 µg / EE 50 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Women with global 'improvement or healing' acne assessment at cycle 6.
Figuras y tablas -
Analysis 19.1

Comparison 19 LNG 250 µg / EE 50 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Women with global 'improvement or healing' acne assessment at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 20 LNG 100 µg / EE 20 µg versus NA 1 mg / EE 20 µg, Outcome 1 Mean change in total lesion count among subset of women with >= 15 lesions at baseline.
Figuras y tablas -
Analysis 20.1

Comparison 20 LNG 100 µg / EE 20 µg versus NA 1 mg / EE 20 µg, Outcome 1 Mean change in total lesion count among subset of women with >= 15 lesions at baseline.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 20 LNG 100 µg / EE 20 µg versus NA 1 mg / EE 20 µg, Outcome 2 Discontinuation due to side effects.
Figuras y tablas -
Analysis 20.2

Comparison 20 LNG 100 µg / EE 20 µg versus NA 1 mg / EE 20 µg, Outcome 2 Discontinuation due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean percentage change in inflammatory lesion count after cycle 6.
Figuras y tablas -
Analysis 21.1

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean percentage change in inflammatory lesion count after cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Mean percentage change in total lesion count after cycle 6.
Figuras y tablas -
Analysis 21.2

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Mean percentage change in total lesion count after cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 3 Improvement of facial acne (clinical assessment).
Figuras y tablas -
Analysis 21.3

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 3 Improvement of facial acne (clinical assessment).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 4 Discontinuation due to reason other than adverse event.
Figuras y tablas -
Analysis 21.4

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 4 Discontinuation due to reason other than adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 5 Discontinuation due to adverse event.
Figuras y tablas -
Analysis 21.5

Comparison 21 Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg, Outcome 5 Discontinuation due to adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 NGM 180‐215‐250 µg / EE 35 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean change in total lesion count at cycle 3.
Figuras y tablas -
Analysis 22.1

Comparison 22 NGM 180‐215‐250 µg / EE 35 µg versus CPA 2 mg / EE 35 µg, Outcome 1 Mean change in total lesion count at cycle 3.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 22 NGM 180‐215‐250 µg / EE 35 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Discontinuation due to adverse event.
Figuras y tablas -
Analysis 22.2

Comparison 22 NGM 180‐215‐250 µg / EE 35 µg versus CPA 2 mg / EE 35 µg, Outcome 2 Discontinuation due to adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Mean change in total acne lesions at cycle 6.
Figuras y tablas -
Analysis 23.1

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 1 Mean change in total acne lesions at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 2 Mean pustule count at cycle 6.
Figuras y tablas -
Analysis 23.2

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 2 Mean pustule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 3 Mean papule count at cycle 6.
Figuras y tablas -
Analysis 23.3

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 3 Mean papule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 4 Mean cyst and nodule count at cycle 6.
Figuras y tablas -
Analysis 23.4

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 4 Mean cyst and nodule count at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 5 Women with dermatologist global "good" acne assessment at cycle 6.
Figuras y tablas -
Analysis 23.5

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 5 Women with dermatologist global "good" acne assessment at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 6 Women with "good" acne self‐assessment at cycle 6.
Figuras y tablas -
Analysis 23.6

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 6 Women with "good" acne self‐assessment at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 7 Women with healed or improved facial acne lesions at cycle 9.
Figuras y tablas -
Analysis 23.7

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 7 Women with healed or improved facial acne lesions at cycle 9.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 8 Women with severe acne score at cycle 12.
Figuras y tablas -
Analysis 23.8

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 8 Women with severe acne score at cycle 12.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 9 Discontinuation due to side effects.
Figuras y tablas -
Analysis 23.9

Comparison 23 CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg, Outcome 9 Discontinuation due to side effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 1 Women with self‐assessed acne improvement at cycle 6.
Figuras y tablas -
Analysis 24.1

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 1 Women with self‐assessed acne improvement at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 2 Women with self‐assessed lack of acne at cycle 6.
Figuras y tablas -
Analysis 24.2

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 2 Women with self‐assessed lack of acne at cycle 6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 3 Discontinuation due to non‐acne adverse event.
Figuras y tablas -
Analysis 24.3

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 3 Discontinuation due to non‐acne adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 4 Discontinuation due to lack of acne improvement.
Figuras y tablas -
Analysis 24.4

Comparison 24 CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg, Outcome 4 Discontinuation due to lack of acne improvement.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. LNG 100 µg / EE 20 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean change in total lesion count Show forest plot

2

572

Mean Difference (IV, Fixed, 95% CI)

‐9.98 [‐16.51, ‐3.45]

2 Mean change in inflammatory lesion count Show forest plot

2

572

Mean Difference (IV, Fixed, 95% CI)

‐2.95 [‐4.97, ‐0.93]

3 Mean change in non‐inflammatory lesion count Show forest plot

2

572

Mean Difference (IV, Fixed, 95% CI)

‐6.75 [‐12.56, ‐0.94]

4 Clinician assessment of women with clear or almost clear lesions at cycle 6 Show forest plot

2

571

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.56 [1.13, 2.18]

5 Participant self‐assessment of acne lesion improvement Show forest plot

2

572

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.13 [1.47, 3.09]

6 Discontinuation due to non‐acne adverse event Show forest plot

1

350

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.54 [0.55, 4.31]

7 Discontinuation due to lack of acne improvement Show forest plot

1

350

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.88 [0.31, 2.47]
Figuras y tablas -
Comparison 1. LNG 100 µg / EE 20 µg versus placebo
Ir a la tabla de la revisión
Comparison 2. NA 1 mg / EE 20‐30‐35 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Clinician assessment of no, minimal or mild acne at cycle 6 Show forest plot

1

555

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.86 [1.32, 2.62]

2 Discontinuation due to any adverse event Show forest plot

1

593

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.73 [1.26, 5.90]
Figuras y tablas -
Comparison 2. NA 1 mg / EE 20‐30‐35 µg versus placebo
Ir a la tabla de la revisión
Comparison 3. NGM 180‐215‐250 µg / EE 35 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean change in total lesion count at cycle 6 Show forest plot

2

387

Mean Difference (IV, Fixed, 95% CI)

‐9.32 [‐14.19, ‐4.45]

2 Mean change in inflammatory lesion count at cycle 6 Show forest plot

2

387

Mean Difference (IV, Fixed, 95% CI)

‐3.44 [‐5.43, ‐1.44]

3 Mean change in comedone count at cycle 6 Show forest plot

2

387

Mean Difference (IV, Fixed, 95% CI)

‐5.81 [‐9.77, ‐1.85]

4 Clinician global assessment of improved acne at cycle 6 Show forest plot

2

324

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.86 [2.31, 6.44]

5 Participant self‐assessment of improved acne at cycle 6 Show forest plot

1

163

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.50 [2.37, 8.56]

6 Discontinuation due to non‐acne adverse event Show forest plot

2

488

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.98 [0.91, 4.30]

7 Discontinuation due to worsening of acne Show forest plot

2

488

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.75 [0.75, 18.71]
Figuras y tablas -
Comparison 3. NGM 180‐215‐250 µg / EE 35 µg versus placebo
Ir a la tabla de la revisión
Comparison 4. Dienogest 2 mg / EE 30 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean percentage change in inflammatory lesion count after cycle 6 Show forest plot

1

768

Mean Difference (IV, Fixed, 95% CI)

‐16.10 [‐21.74, ‐10.46]

2 Mean percentage change in total lesion count after cycle 6 Show forest plot

1

774

Mean Difference (IV, Fixed, 95% CI)

‐15.30 [‐19.98, ‐10.62]

3 Improvement of facial acne (clinical assessment) Show forest plot

1

780

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.87 [2.50, 5.99]

4 Discontinuation due to adverse event Show forest plot

1

789

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.33 [0.38, 4.67]

5 Discontinuation due to reason other than adverse event Show forest plot

1

789

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.40 [0.18, 0.86]
Figuras y tablas -
Comparison 4. Dienogest 2 mg / EE 30 µg versus placebo
Ir a la tabla de la revisión
Comparison 5. DRSP 3 mg / EE 20 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean percent change in lesion counts at cycle 6 Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 Mean percent change in total lesion count

1

173

Mean Difference (IV, Fixed, 95% CI)

29.08 [3.13, 55.03]

1.2 Mean percent change in inflammatory lesion count

1

146

Mean Difference (IV, Fixed, 95% CI)

14.61 [5.18, 24.04]

1.3 Mean percent change in non‐inflammatory lesion count

1

146

Mean Difference (IV, Fixed, 95% CI)

19.03 [5.13, 32.93]

1.4 Mean percent change in papule count

1

146

Mean Difference (IV, Fixed, 95% CI)

17.33 [5.60, 29.06]

1.5 Mean percent change in pustule count

1

125

Mean Difference (IV, Fixed, 95% CI)

1.73 [‐11.48, 14.94]

1.6 Mean percent change in nodule count

1

62

Mean Difference (IV, Fixed, 95% CI)

0.83 [‐8.80, 10.46]

1.7 Mean percent change in open comedone count

1

141

Mean Difference (IV, Fixed, 95% CI)

‐14.28 [‐84.76, 56.20]

1.8 Mean percent change in closed comedone count

1

145

Mean Difference (IV, Fixed, 95% CI)

20.79 [3.57, 38.01]

2 Clear or almost clear (investigator assessment) at cycle 6 Show forest plot

2

575

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.02 [1.99, 4.59]

3 Participants classified as 'improved' at cycle 6 Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

3.1 Investigator assessment

1

152

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.67 [1.46, 9.20]

3.2 Participant assessment

1

152

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.06 [1.06, 8.85]

4 Discontinuation Show forest plot

3

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

4.1 Due to adverse event

3

1251

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.57 [0.94, 2.62]

4.2 Due to reason other than adverse event

1

179

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.71 [0.28, 1.84]
Figuras y tablas -
Comparison 5. DRSP 3 mg / EE 20 µg versus placebo
Ir a la tabla de la revisión
Comparison 6. CMA 2 mg / EE 30 µg versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Responders (>= 50% decrease in facial papules and pustules) at cycle 6 Show forest plot

1

377

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.31 [1.50, 3.55]

2 Discontinuation due to adverse event Show forest plot

1

377

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.49 [1.17, 10.40]
Figuras y tablas -
Comparison 6. CMA 2 mg / EE 30 µg versus placebo
Ir a la tabla de la revisión
Comparison 7. DRSP 3 mg / EE 30 µg versus CPA 2 mg / EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean percentage change in total acne count at cycle 9 Show forest plot

1

118

Mean Difference (IV, Fixed, 95% CI)

‐2.5 [‐26.96, 21.96]
Figuras y tablas -
Comparison 7. DRSP 3 mg / EE 30 µg versus CPA 2 mg / EE 35 µg
Ir a la tabla de la revisión
Comparison 8. DRSP 3 mg / EE 30 µg versus LNG 150 µg / EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Discontinuation due to acne deterioration Show forest plot

1

424

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.16 [0.05, 0.47]
Figuras y tablas -
Comparison 8. DRSP 3 mg / EE 30 µg versus LNG 150 µg / EE 30 µg
Ir a la tabla de la revisión
Comparison 9. DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean percentage change in inflammatory lesion count after cycle 6 Show forest plot

1

1108

Mean Difference (IV, Fixed, 95% CI)

‐2.40 [‐5.97, 1.17]

2 Mean percentage change in total lesion count after cycle 6 Show forest plot

1

1108

Mean Difference (IV, Fixed, 95% CI)

‐3.30 [‐6.45, ‐0.15]

3 Discontinuation due to adverse event Show forest plot

1

1148

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.80 [0.43, 1.49]

4 Discontinuation due to reason other than adverse event Show forest plot

1

1148

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.97 [0.50, 1.90]

5 Improvement of facial acne (clinical assessment) Show forest plot

1

1120

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.85 [1.14, 3.01]

6 Improvement of facial acne (subject assessment) Show forest plot

1

1117

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.64 [1.09, 2.47]
Figuras y tablas -
Comparison 9. DRSP 3 mg / EE 30 µg versus NGM 180‐215‐250 µg / EE 35 µg
Ir a la tabla de la revisión
Comparison 10. NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Clinician assessment of improved acne after cycle 13 (all participants) Show forest plot

1

2083

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.74 [0.57, 0.96]

2 Clinician assessment of worsening acne after cycle 13 (all participants) Show forest plot

1

2083

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.14 [1.49, 3.05]

3 Clinician assessment of improved acne after cycle 13 (participants with acne at baseline) Show forest plot

1

683

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.60 [0.42, 0.84]

4 Clinician assessment of worsening acne after cycle 13 (participants with acne at baseline) Show forest plot

1

683

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.69 [1.29, 5.63]

5 Clinician assessment of new acne after cycle 13 (participants without acne at baseline) Show forest plot

1

1400

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.00 [1.33, 3.01]

6 Discontinuation due to adverse events Show forest plot

1

2126

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.77 [1.36, 2.30]

7 Discontinuation due to acne Show forest plot

1

2126

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.56 [1.91, 6.63]
Figuras y tablas -
Comparison 10. NOMAC 2 mg / E2 1.5 mg versus DRSP 3 mg / EE 30 µg
Ir a la tabla de la revisión
Comparison 11. DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Photographic evaluation of mean change in acne at cycle 4 Show forest plot

1

99

Mean Difference (IV, Fixed, 95% CI)

0.1 [‐0.10, 0.30]

2 Women with pustules or nodules at cycle 4 Show forest plot

1

121

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.27 [0.62, 2.58]

3 Mean change in comedone count at cycle 4 Show forest plot

1

121

Mean Difference (IV, Fixed, 95% CI)

3.70 [‐5.39, 12.79]

4 Mean change in papule count at cycle 4 Show forest plot

1

121

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐4.16, 2.96]

5 Mean change in pustule count at cycle 4 Show forest plot

1

121

Mean Difference (IV, Fixed, 95% CI)

2.30 [‐0.15, 4.75]

6 Women with moderate acne at cycle 6 Show forest plot

1

136

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.19 [0.61, 2.34]

7 Women with severe acne at cycle 6 Show forest plot

1

136

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.00 [0.39, 10.21]

8 Mean comedone count at cycle 6 Show forest plot

1

136

Mean Difference (IV, Fixed, 95% CI)

2.90 [0.05, 5.75]

9 Mean papule count at cycle 6 Show forest plot

1

136

Mean Difference (IV, Fixed, 95% CI)

1.80 [‐0.40, 4.00]

10 Mean postule count at cycle 6 Show forest plot

1

136

Mean Difference (IV, Fixed, 95% CI)

0.80 [‐0.35, 1.95]

11 Mean nodule count at cycle 6 Show forest plot

1

136

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.18, 0.18]

12 Discontinuation due to non‐acne adverse event Show forest plot

1

172

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.60 [0.45, 5.73]

13 Discontinuation due to worsening of acne Show forest plot

1

172

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.05 [0.06, 16.90]
Figuras y tablas -
Comparison 11. DSG 25‐125 µg / EE 40‐30 µg versus CPA 2 mg / EE 35 µg
Ir a la tabla de la revisión
Comparison 12. DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Women with moderate or severe acne at cycle 6 Show forest plot

1

57

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.35 [1.96, 20.52]

2 Women with self‐assessed acne improvement at cycle 6 Show forest plot

1

57

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.41 [0.32, 18.18]

3 Discontinuation due to side effects Show forest plot

1

66

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.12 [0.21, 21.13]
Figuras y tablas -
Comparison 12. DSG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg
Ir a la tabla de la revisión
Comparison 13. DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Women without acne at cycle 6 Show forest plot

2

1180

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.17 [0.82, 1.66]

2 Women with mild acne at cycle 6 Show forest plot

2

1180

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.76 [0.52, 1.10]

3 Women with moderate or severe acne at cycle 6 Show forest plot

2

1180

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.78 [0.73, 4.32]

4 Women with mild or no acne at cycle 9 Show forest plot

1

19

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.05 [0.57, 44.42]

5 Women with improved acne score at cycle 9 Show forest plot

1

19

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.41 [0.08, 25.31]

6 Discontinuation due to side effects Show forest plot

2

1378

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.61 [0.40, 0.93]
Figuras y tablas -
Comparison 13. DSG 150 µg / EE 30 µg versus GSD 75 µg / EE 30 µg
Ir a la tabla de la revisión
Comparison 14. DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Improvement in comedones at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.55 [1.03, 2.32]

2 Worsening in comedones at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.80 [0.46, 1.37]

3 Improvement in papules at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.00 [0.67, 1.50]

4 Worsening in papules at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.60 [0.37, 0.96]

5 Improvement in pustules at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.47 [0.91, 2.38]

6 Worsening in pustules at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.65 [0.37, 1.13]

7 Improvement in nodules at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.79 [0.38, 1.63]

8 Worsening in nodules at week 25 Show forest plot

1

524

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.11 [0.40, 3.10]

9 Scores for Psychological General Well‐Being Index at week 13 Show forest plot

1

720

Mean Difference (IV, Fixed, 95% CI)

1.90 [0.26, 3.54]

10 Scores for Psychological General Well‐Being Index at week 25 Show forest plot

1

516

Mean Difference (IV, Fixed, 95% CI)

1.1 [‐0.83, 3.03]

11 Adverse events related to treatment Show forest plot

1

998

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.96 [0.58, 1.60]

12 Adverse events not related to treatment Show forest plot

1

998

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.42 [0.99, 2.04]
Figuras y tablas -
Comparison 14. DSG 150 µg / EE 20 µg versus LNG 100 µg / EE 20 µg
Ir a la tabla de la revisión
Comparison 15. LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean acne severity score at cycle 6 Show forest plot

1

33

Mean Difference (IV, Fixed, 95% CI)

0.5 [0.09, 0.91]

2 Mean total lesion count at cycle 9 Show forest plot

1

16

Mean Difference (IV, Fixed, 95% CI)

6.30 [‐9.93, 22.53]

3 Discontinuation due to side effects Show forest plot

1

34

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.0 [0.06, 16.69]

4 Discontinuation due to worsening acne Show forest plot

1

54

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.93 [0.36, 10.36]
Figuras y tablas -
Comparison 15. LNG 150 µg / EE 30 µg versus DSG 150 µg / EE 30 µg
Ir a la tabla de la revisión
Comparison 16. LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Women with >= 50% reduction in pustules and papules at cycle 12 Show forest plot

1

199

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.58 [0.33, 1.02]

2 Women with Plewig score of 0 at cycle 12 Show forest plot

1

149

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.59 [0.30, 1.13]

3 Women with increased pustules or papules lesion count at cycle 12 Show forest plot

1

149

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.34 [2.25, 38.73]

4 Women with comedones improvement at cycle 12 Show forest plot

1

138

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.44 [0.18, 1.06]

5 Women with self‐assessed acne improvement at cycle 12 Show forest plot

1

149

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.16 [0.04, 0.57]
Figuras y tablas -
Comparison 16. LNG 150 µg / EE 30 µg versus CMA 2 mg / EE 30 µg
Ir a la tabla de la revisión
Comparison 17. LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean change in total acne lesions at cycle 6 Show forest plot

1

80

Mean Difference (IV, Fixed, 95% CI)

2.50 [‐8.81, 13.81]

2 Mean pustule count at cycle 6 Show forest plot

1

80

Mean Difference (IV, Fixed, 95% CI)

1.80 [0.63, 2.97]

3 Mean papule count at cycle 6 Show forest plot

1

80

Mean Difference (IV, Fixed, 95% CI)

2.90 [0.20, 5.60]

4 Mean cyst and nodule count at cycle 6 Show forest plot

1

80

Mean Difference (IV, Fixed, 95% CI)

0.40 [‐0.13, 0.93]

5 Women with dermatologist global "good" acne assessment at cycle 6 Show forest plot

1

81

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.29 [0.12, 0.68]

6 Women with "good" acne self‐assessment at cycle 6 Show forest plot

1

80

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.23 [0.09, 0.54]

7 Discontinuation due to side effects Show forest plot

1

85

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.35 [0.40, 4.60]
Figuras y tablas -
Comparison 17. LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 35 µg
Ir a la tabla de la revisión
Comparison 18. LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean change in total acne lesions at cycle 6 Show forest plot

1

81

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐10.79, 10.99]

2 Mean pustule count at cycle 6 Show forest plot

1

81

Mean Difference (IV, Fixed, 95% CI)

2.10 [0.93, 3.27]

3 Mean papule count at cycle 6 Show forest plot

1

82

Mean Difference (IV, Fixed, 95% CI)

3.60 [1.12, 6.08]

4 Mean cyst and nodule count at cycle 6 Show forest plot

1

81

Mean Difference (IV, Fixed, 95% CI)

0.40 [‐0.11, 0.91]

5 Women with dermatologist global "good" acne assessment at cycle 6 Show forest plot

1

81

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.09, 0.52]

6 Women with "good" acne self‐assessment at cycle 6 Show forest plot

1

81

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.18 [0.08, 0.44]

7 Discontinuation due to side effects Show forest plot

1

85

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.66 [0.47, 5.92]
Figuras y tablas -
Comparison 18. LNG 150 µg / EE 30 µg versus CPA 2 mg / EE 50 µg
Ir a la tabla de la revisión
Comparison 19. LNG 250 µg / EE 50 µg versus CPA 2 mg / EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Women with global 'improvement or healing' acne assessment at cycle 6 Show forest plot

1

75

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.24 [0.08, 0.75]
Figuras y tablas -
Comparison 19. LNG 250 µg / EE 50 µg versus CPA 2 mg / EE 50 µg
Ir a la tabla de la revisión
Comparison 20. LNG 100 µg / EE 20 µg versus NA 1 mg / EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean change in total lesion count among subset of women with >= 15 lesions at baseline Show forest plot

1

19

Mean Difference (IV, Fixed, 95% CI)

2.5 [‐12.26, 17.26]

2 Discontinuation due to side effects Show forest plot

1

58

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.13 [0.00, 6.37]
Figuras y tablas -
Comparison 20. LNG 100 µg / EE 20 µg versus NA 1 mg / EE 20 µg
Ir a la tabla de la revisión
Comparison 21. Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean percentage change in inflammatory lesion count after cycle 6 Show forest plot

1

1037

Mean Difference (IV, Fixed, 95% CI)

‐1.0 [‐4.72, 2.72]

2 Mean percentage change in total lesion count after cycle 6 Show forest plot

1

1043

Mean Difference (IV, Fixed, 95% CI)

‐1.10 [‐4.37, 2.17]

3 Improvement of facial acne (clinical assessment) Show forest plot

1

1051

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.23 [0.80, 1.88]

4 Discontinuation due to reason other than adverse event Show forest plot

1

1062

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.75 [0.37, 1.50]

5 Discontinuation due to adverse event Show forest plot

1

1062

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.56 [0.78, 8.40]
Figuras y tablas -
Comparison 21. Dienogest 2 mg / EE 30 µg versus CPA 2 mg / EE 35 µg
Ir a la tabla de la revisión
Comparison 22. NGM 180‐215‐250 µg / EE 35 µg versus CPA 2 mg / EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean change in total lesion count at cycle 3 Show forest plot

1

45

Mean Difference (IV, Fixed, 95% CI)

‐9.16 [‐24.98, 6.66]

2 Discontinuation due to adverse event Show forest plot

1

45

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.97 [0.47, 18.90]
Figuras y tablas -
Comparison 22. NGM 180‐215‐250 µg / EE 35 µg versus CPA 2 mg / EE 35 µg
Ir a la tabla de la revisión
Comparison 23. CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mean change in total acne lesions at cycle 6 Show forest plot

1

89

Mean Difference (IV, Fixed, 95% CI)

‐2.40 [‐7.15, 2.35]

2 Mean pustule count at cycle 6 Show forest plot

1

89

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐0.34, 0.94]

3 Mean papule count at cycle 6 Show forest plot

1

90

Mean Difference (IV, Fixed, 95% CI)

0.70 [‐1.47, 2.87]

4 Mean cyst and nodule count at cycle 6 Show forest plot

1

89

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.25, 0.25]

5 Women with dermatologist global "good" acne assessment at cycle 6 Show forest plot

1

90

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.75 [0.31, 1.77]

6 Women with "good" acne self‐assessment at cycle 6 Show forest plot

1

89

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.78 [0.32, 1.94]

7 Women with healed or improved facial acne lesions at cycle 9 Show forest plot

1

425

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.16 [0.79, 1.70]

8 Women with severe acne score at cycle 12 Show forest plot

1

73

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.94 [0.48, 17.99]

9 Discontinuation due to side effects Show forest plot

1

96

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.23 [0.35, 4.27]
Figuras y tablas -
Comparison 23. CPA 2 mg / EE 35 µg versus CPA 2 mg / EE 50 µg
Ir a la tabla de la revisión
Comparison 24. CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Women with self‐assessed acne improvement at cycle 6 Show forest plot

1

78

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.48 [0.43, 5.01]

2 Women with self‐assessed lack of acne at cycle 6 Show forest plot

1

78

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.85 [0.28, 2.60]

3 Discontinuation due to non‐acne adverse event Show forest plot

1

98

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.36 [0.29, 6.26]

4 Discontinuation due to lack of acne improvement Show forest plot

1

98

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.66 [0.11, 3.95]
Figuras y tablas -
Comparison 24. CPA 2 mg / EE 50 µg versus minocycline hydrochloride 50 mg
Ir a la tabla de la revisión